Abstracts tagged "menopause"

Abstract Number: 361 • 2015 ACR/ARHP Annual Meeting
Sodium Intake and Osteoporosis. Findings from the Women’s Health Initiative
Laura Carbone¹, Karen Johnson², Ying Huang³, Mary Pettinger⁴, Thomas Fridtjof⁵, Jane A. Cauley⁶, Carolyn Crandall⁷, Lesley Tinker⁸, Meryl LeBoff⁹, Jean Wactawksi-Wende¹⁰, Monique Bethel¹¹, Wenjun Li¹² and Ross Prentice³, ¹Rheumatology, Georgia Regents University, Augusta, GA, ²Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, ³Biostatistics, University of Washington, Seattle, WA, ⁴Fred Hutcinson Cancer Research Center, Seattle, WA, ⁵University of Tennessee Health Science Center, Memphis, TN, ⁶Department of Epidemiology, Univ of Pittsburgh, Pittsburgh, PA, ⁷Medicine, University of California Los Angeles, Los Angeles, CA, ⁸Fred Hutchinson Cancer Research Center, Seattle, WA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰University of Buffalo, Buffalo, NY, ¹¹Internal Medicine, Georgia Regents University, Augusta, GA, ¹²Medicine, Division of Preventive Medicine, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: The relationship of sodium intake to bone mineral density (BMD) in postmenopausal women has not been established, and no study to date has examined…
Abstract Number: 2887 • 2014 ACR/ARHP Annual Meeting
Post-Menopausal Factors and the Risk of Seropositive and Seronegative Rheumatoid Arthritis Phenotypes: Results from the Nurses’ Health Study
Camilla Bengtsson¹, Susan Malspeis², Jeffrey A. Sparks³, Karen H. Costenbader³ and Elizabeth W. Karlson³, ¹The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Among women, the peak incidence of rheumatoid arthritis (RA) is reported to be 45-74 years of age. In addition, it has been suggested that…
Abstract Number: 2261 • 2014 ACR/ARHP Annual Meeting
A Meta-Anlaysis of Bisphosphonate and Parathyroid Hormone (PTH) Use in Osteoporosis
Zsolt Kulcsar¹, Lena Saleh², Shravani Gangidi³ and Poonam Khadka⁴, ¹Rheumatology/Leadership Preventive Medicine Residency, Dartmouth Hitchcock Medical Center, lebanon, NH, ²The Dartmouth Institute For Healthcare Policy and Clinical Practice, Lebanon, NH, ³The Dartmouth Institute For Healthcare Policy and Clinical Practice, lebanon, NH, ⁴Endocrinology, Dartmouth Hitchcock Medical Center, lebanon, NH
Background/Purpose: Bisphosphonates are currently the drug of choice for treatment of osteoporosis. While anabolic agents like parathyroid hormone (PTH) have shown greater improvements in bone…
Abstract Number: 2262 • 2014 ACR/ARHP Annual Meeting
Raloxifene for Osteoporosis in Postmenopausal Women with Rheumatic Diseases
Won Seok Lee¹, Yun Jung Choi², Yun-Hong Cheon¹, Myong-Joo Hong³, Chang-Hoon Lee⁴, Myeung Su Lee⁴, Sang-Il Lee⁵ and Wan-Hee Yoo⁶, ¹Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ²Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, JeonJu, South Korea, ³Department of internal Medicine, Presbyterian Medical center, Jeonju, South Korea, ⁴Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea, ⁶Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea
Background/Purpose : Raloxifen is a selective estrogen receptor modulator that has been extensively studied. We studied the efficacy of raloxifene on disease activity and bone…
Abstract Number: 2915 • 2013 ACR/ARHP Annual Meeting
Effect Of Menopause On Skin Thickening In Systemic Sclerosis
Evelyne Vinet¹, Sasha Bernatsky², Christian A. Pineau³, Marie Hudson⁴, Murray Baron⁵ and the Canadian Scleroderma Research Group⁶, ¹McGill University Health Center, Montreal, QC, Canada, ²Division of Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada, ³Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁴Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Menopause, characterized by a low estrogenic state, is associated with skin thinning, due to decreased extracellular matrix protein deposition by fibroblasts. Although systemic sclerosis…
Abstract Number: 1407 • 2013 ACR/ARHP Annual Meeting
High Serum Cholesterol Predicts Rheumatoid Arthritis In Women
Carl Turesson¹, Ulf Bergström², Mitra Pikwer², Jan-Åke Nilsson² and Lennart Jacobsson², ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Patients with active rheumatoid arthritis (RA) tend to have low cholesterol levels due to effects of inflammation on lipid metabolism. However, several prospective studies…
Abstract Number: 373 • 2013 ACR/ARHP Annual Meeting
Menopause Occurs Earlier and Is An Independent Risk Factor For Osteoporosis In Women With Rheumatoid Arthritis
Michael Cocker¹, Alexander Oldroyd² and Marwan Bukhari³, ¹Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ³Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) and early menopause (
Abstract Number: 117 • 2013 ACR/ARHP Annual Meeting
Postmenopausal Hormone Therapy and The Risk Of Rheumatoid Arthritis: Results From The Swedish EIRA Study
Cecilia Orellana¹, Saedis Saevarsdottir^1,2, Lars Klareskog³, Lars Alfredsson¹ and Camilla Bengtsson¹, ¹Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ³Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
Background/Purpose: The importance of hormonal/reproductive factors has been hypothesized to contribute to the risk of Rheumatoid arthritis (RA), but the literature is somewhat contradictory. The…
Abstract Number: 156 • 2012 ACR/ARHP Annual Meeting
Menopause and the Prevalence of Gout and Hyperuricemia: An Age-Matched Case Control Study
Eswar Krishnan¹ and Mihoko Bennett², ¹Medicine, Standford University, Palo Alto, CA, ²Pediatrics, Stanford University, Palo Alto, CA
Background/Purpose: Among women, the prevalence of gouty arthritis (gout) and hyperuricemia (serum urate>6.0 mg/dL) increases steeply after the age 60. This increase has been attributed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].